管理肥胖相关男性不育:减重干预的启示
本小型综述总结生活方式干预、减重手术及胰高血糖素样肽-1(GLP-1)受体激动剂等治疗对男性生育结局的影响。生活方式干预为一线治疗,减重手术可升高睾酮但亦有精子浓度下降和术后无精子症报告,GLP-1受体激动剂可能改善精子活力但存在可逆性精液质量受损个案,尚需纵向研究明确生育改善是否转化为更高受孕率。
要点
- 生活方式干预(中等强度运动及饮食改善)为一线治疗,应常规鼓励。
- 减重手术升高睾酮,但亦有精子浓度下降和术后无精子症报告,需术前生育咨询并考虑精子冷冻保存。
- GLP-1受体激动剂可能改善精子活力和激素标志物,但有个案报告可逆性精液质量受损。
核心结论
- 生活方式干预、减重手术和GLP-1受体激动剂对男性生育结局有潜在益处,但观察到的获益是否源于减重本身还是特定治疗方式尚不清楚。
- 需要纵向研究确定生育改善是否转化为更高受孕率,GLP-1受体激动剂在孕前期的生殖安全性也需进一步研究。
- 作者建议优先开展以功能性生育终点为指标的实用性临床试验,以及在特征明确的男性肥胖表型中开展机制研究和子代健康评估。
- 最终需要从狭隘关注减重转向更广泛强调改善代谢健康,个性化方法结合行为咨询和多学科护理对推进肥胖相关男性不育治疗至关重要。
研究设计与样本
- 本小型综述总结当前证据,涉及生活方式调整、减重手术和GLP-1受体激动剂等药物方法对男性生育结局的影响。
主要发现
- 生活方式干预,特别是中等强度运动及饮食改善,为一线治疗,应常规鼓励。
- 热量限制和富含抗氧化剂的地中海式饮食与精液质量和激素平衡改善相关。
- 减重手术升高睾酮水平,并可能改善部分男性的精子质量和辅助生殖结局,但也有精子浓度下降和术后无精子症病例报告。
- GLP-1受体激动剂促进减重,可能改善精子活力和激素标志物,但有个案报告可逆性精液质量受损。
临床怎么用
- 生活方式干预,特别是中等强度运动及饮食改善,为一线治疗,应常规鼓励。
- 减重手术前应进行生育咨询并考虑精子冷冻保存。
- 作者建议优先开展以功能性生育终点为指标的实用性临床试验,以及在特征明确的男性肥胖表型中开展机制研究和子代健康评估。
局限性
- 尽管这些干预措施的临床应用日益增多,但观察到的获益是否源于减重本身还是特定治疗方式尚不清楚。
- 需要纵向研究确定生育改善是否转化为更高受孕率。
- GLP-1受体激动剂在孕前期的生殖安全性也需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity is a global health concern with major implications for male reproductive function. It disrupts endocrine and metabolic homeostasis, impairs semen quality, and is associated with reduced pregnancy and live birth rates. Hormonal imbalances, inflammation, and lipid stress are key contributors to these impairments. This mini-review summarizes current evidence on the impact of therapeutic interventions, including lifestyle modification, bariatric surgery, and pharmacological approaches such as glucagon-like peptide-1 (GLP-1) receptor agonists, on male fertility outcomes. Lifestyle interventions, particularly moderate-intensity exercise and dietary improvements, are first-line therapies and should be routinely encouraged. Caloric restriction and Mediterranean-style diets rich in antioxidants have been associated with improved semen quality and hormonal balance. Bariatric surgery raises testosterone levels and may improve sperm quality and assisted reproduction outcomes in some men, but declines in sperm concentration and cases of postoperative azoospermia have also been reported. These findings underscore the importance of preoperative fertility counselling and consideration of sperm cryopreservation. GLP-1 receptor agonists promote weight loss and may improve sperm motility and hormonal markers; however, isolated cases of reversible impairment in sperm quality have been reported. Despite growing clinical use of these interventions, it remains unclear whether the observed benefits stem from weight loss itself or the specific treatment modalities. Longitudinal studies are needed to determine whether fertility improvements translate into higher conception rates. The reproductive safety of GLP-1 agonists in the preconception period also warrants further investigation. We recommend prioritizing pragmatic clinical trials with functional fertility endpoints, as well as mechanistic studies in well-characterized male obesity phenotypes and evaluation of offspring health. Ultimately, a shift is necessary from a narrow focus on weight loss to a broader emphasis on enhancing metabolic health. Personalized approaches tailored towards hormonal profiles, comorbidities, and fertility goals, supported by behavioural counselling and multidisciplinary care, are essential for advancing the treatment of obesity-related male infertility.
引用
- Pereira TA, Thaker N, Rubez AC, et al. Managing obesity-related male infertility: insights from weight loss intervention. Hum Reprod. 2025. PMID: 41024420. doi:10.1093/humrep/deaf180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。